FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	.C. 20549	
---------------	-----------	--

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPRO	OVAL
	OMB Number:	3235-0287
l	Estimated average burd	en
	hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* KLEIN JOSEPH III					2. Issuer Name and Ticker or Trading Symbol PDL BIOPHARMA, INC. [PDLI]									Check al	ationship of Reporti c all applicable) Director Officer (give title below)		10% Ov		wner	
(Last) (First) (Middle) C/O PDL BIOPHARMA, INC. 1400 SEAPORT BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 02/06/2008													Other (speci below)			
(Street) REDWO CITY (City)	C.F		04063 Zip)		4. If	f Ame	endmer	it, Date o	of Origina	l Filed	(Month/Da	ay/Yea	ır)		ine) X	orm=	Joint/Group filed by One filed by Mor on	e Rep	porting Pers	on
		Tabl	e I - Nor	n-Deriv	ative	Se	curit	es Ac	quired	Dis	posed o	f, or	Ben	efici	ally O	vne	d			
Date			Date	th/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code	Transaction Code (Instr.					and Se B	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount		A) or D)	Price	, Tr	ansa	nsaction(s) tr. 3 and 4)			(111511.4)
Common Stock 02/				02/06	5/2008						500		A	\$1	4.2	6,500			D	
Common Stock															1			I	By Trust	
Common Stock												10			I	By Wife				
		Та									sed of, onvertib					ed				
2. Title of Derivative Security Instr. 3) 2. Conversion Date (Month/Day/Year) 3. Transaction Date Execution Date, if any (Month/Day/Year)		4. Transa Code (8)		ion of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration (Month/I	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amount of Mumbb of Title Shares		8. Price Derivat Securit (Instr. !	ive			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

Explanation of Responses:

1. Purchase was made pursuant to a 10b5-1 plan established by the reporting person.

Remarks:

/s/ Francis Sarena by Francis Sarena, Attorney-in-Fact for

Joseph Klein III

** Signature of Reporting Person Date

02/06/2008

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.